# Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

> **NCT04884906** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Locally Advanced Cervical Cancer

## Interventions

- **BIOLOGICAL:** Camrelizumab
- **RADIATION:** radiotherapy
- **DRUG:** Albumin Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04884906
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2022-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04884906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04884906, "Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04884906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*